Synthetic lethality between CCNE1 amplification and loss of BRCA1

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 48, 2013, Pages 19489-19494

  Etemadmoghadam, Dariush ^a,b   Weir, Barbara A ^c,d   Au Yeung, George ^a,b   Alsop, Kathryn ^a,b   Mitchell, Gillian ^a,b   George, Joshy ^a,b   Davis, Sally ^a,b   D'Andrea, Alan D ^c   Simpson, Kaylene ^a,b   Hahn, William C ^c,d   Bowtell, David D L ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

CDK2; Cell cycle; DNA repair; Pan cancer; RNAi

Indexed keywords

BORTEZOMIB; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN E; CYCLIN E1; SHORT HAIRPIN RNA; UBIQUITIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE REPRESSION; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; LETHALITY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN DEPLETION; SOMATIC MUTATION;

CDK2; CELL CYCLE; DNA REPAIR; PAN-CANCER; RNAI;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; BRCA1 PROTEIN; CYCLIN E; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMOLOGOUS RECOMBINATION; HUMANS; MICROARRAY ANALYSIS; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RNA, SMALL INTERFERING;

EID: 84888349734     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1314302110     Document Type: Article

References (29)

1. Bowtell DDL (2010) The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10(11): 803-808.
2. Etemadmoghadam D, et al. (2009) Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res 15(4): 1417-1427.
3. Mayr D, et al. (2006) Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. Am J Clin Pathol 126(1): 101-109.
4. Caldon CE, Musgrove EA (2010) Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer. Cell Div 5:2.
5. Etemadmoghadam D, et al. (2010) Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS One 5(11):e15498.
6. Nakayama N, et al. (2010) Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 116(11): 2621-2634.
7. Etemadmoghadam D, et al. (2013) Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1 amplified ovarian cancer. Clin Cancer Res 19(21): 5960-5971.
8. Natrajan R, et al. (2012) Functional characterization of the 19q12 amplicon in grade III breast cancers. Breast Cancer Res 14(2):R53.
9. Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353): 609-615.
10. Ciriello G, Cerami E, Sander C, Schultz N (2012) Mutual exclusivity analysis identifies oncogenic network modules. Genome Res 22(2): 398-406.
11. Roy R, Chun J, Powell SN (2012) BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat Rev Cancer 12(1): 68-78.
12. Theurillat J-P, et al. (2011) URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell 19(3): 317-332.
13. Alsop K, et al. (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30(21): 2654-2663.
14. George J, et al. (2013) Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res 19(13): 3474-3484.
15. Akli S, Keyomarsi K (2003) Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther 2(4 Suppl 1):S38-S47.
16. Cheung HW, et al. (2011) Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci USA 108(30): 12372-12377.
17. Aguirre-Portolés C, et al. (2012) Tpx2 controls spindle integrity, genome stability, and tumor development. Cancer Res 72(6): 1518-1528.
18. Davis SJ, et al. (2013) Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer. Clin Cancer Res 19(6): 1411-1421.
19. Jacquemont C, Simon JA, D'Andrea AD, Taniguchi T (2012) Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. Mol Cancer 11(1):26.
20. Barretina J, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391): 603-607.
21. Shih IeM, Kurman RJ (2004) Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am J Pathol 164(5): 1511-1518.
22. Davies H, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892): 949-954.
23. Luo J, et al. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137(5): 835-848.
24. Aghajanian C, et al. (2009) A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study. Gynecol Oncol 115(2): 215-220.
25. Mermel CH, et al. (2011) GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 12(4):R41.
26. Olshen AB, Venkatraman ES, Lucito R, Wigler M (2004) Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5(4): 557-572.
27. Gautier L, Cope L, Bolstad BM, Irizarry RA (2004) affy - analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20(3): 307-315.
28. Luo B, et al. (2008) Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci USA 105(51): 20380-20385.
29. Masibay A, Mozer TJ, Sprecher C (2000) Promega Corporation reveals primer sequences in its testing kits. J Forensic Sci 45(6): 1360-1362.